echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Optimizing the layout: drug parameters that new drug R&D workers should pay attention to

    Optimizing the layout: drug parameters that new drug R&D workers should pay attention to

    • Last Update: 2021-07-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


















    05


    Reduce side effects


    Medicinal chemistry and organic chemistry have certain similarities, but there are far more uncertain factors in medicinal chemistry than organic chemistry
    .
    Organic chemistry can infer the possible reaction mechanism through structure, but medicinal chemistry cannot predict the biological activity of a compound through structure, and it cannot predict its toxic and side effects
    .
    Compound 18 is an H1 receptor blocker, which can inhibit the potassium channel of the heart and prolong the QT wave.
    However, because the derivative can cause arrhythmia and even sudden death, it was withdrawn from the market
    .
    Studies on its pharmacokinetics have found that after a methyl group in its tert-butyl group is easily metabolized into a carboxyl group, it is still an H1 receptor blocker, but it does not inhibit the hERG channel, so it becomes a second-generation antihistamine.

    .


    summary


    Biological activity is the basis of drugs, and water solubility, oil-water partition coefficient, dissociability, metabolic pathways, and toxic and side effects are necessary conditions for whether a compound can eventually become a drug.
    The two are mutually dependent
    .


    Reference


    1.
    L-735,524:the design of a potent and orally bioavailable HIV protease inhibitor.
    J Med Chem


    2.
    Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloprotease inhibitors.
    J Med Chem


    3.
    Discovery of 1-(3'-amino-benzisoxazol-5'-yl)-3-trifluoromethyl-N-(2-fluoro-4-((2'-dime-thylaminomethyl)imidazol-1-yl)phenyl) -1H-pyrazole-5-carboxy-amide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor.
    J Med Chem


    4.
    Cyclopropylamino acid amide as a pharmacophoric replacement for 2, 3-diamino-


    pyridine.
    Application to the design of novel bradykinin B1 receptor antagonists.
    J Med Chem


    5.
    From serendipity to rational antituberculosis drug discovery of mefloquine-isoxazole car-boxylic acid esters.
    J Med Chem.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.